See more : TMC the metals company Inc. (TMCWW) Income Statement Analysis – Financial Results
Complete financial analysis of Bal Pharma Limited (BALPHARMA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bal Pharma Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- MLP SE (MLP.DE) Income Statement Analysis – Financial Results
- Orora Limited (ORRAF) Income Statement Analysis – Financial Results
- Green Energy Resources, Inc. (GRGR) Income Statement Analysis – Financial Results
- ViewCast.com, Inc. (VCST) Income Statement Analysis – Financial Results
- Al Moammar Information Systems Company (7200.SR) Income Statement Analysis – Financial Results
Bal Pharma Limited (BALPHARMA.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.balpharma.com
About Bal Pharma Limited
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.39B | 3.04B | 2.81B | 2.51B | 1.71B | 2.25B | 2.09B | 2.29B | 1.98B | 1.87B | 1.79B | 1.48B | 1.40B | 1.14B | 1.06B | 1.03B | 857.35M |
| Cost of Revenue | 2.62B | 1.73B | 1.70B | 1.51B | 856.05M | 1.20B | 1.02B | 1.17B | 1.08B | 992.04M | 952.32M | 789.45M | 768.02M | 615.28M | 600.00M | 532.07M | 428.70M |
| Gross Profit | 770.20M | 1.31B | 1.11B | 993.03M | 854.90M | 1.05B | 1.07B | 1.12B | 903.45M | 879.54M | 836.40M | 689.70M | 628.85M | 527.64M | 462.25M | 502.71M | 428.65M |
| Gross Profit Ratio | 22.70% | 43.21% | 39.64% | 39.64% | 49.97% | 46.53% | 51.18% | 48.86% | 45.56% | 46.99% | 46.76% | 46.63% | 45.02% | 46.17% | 43.52% | 48.58% | 50.00% |
| Research & Development | 0.00 | 49.19M | 32.04M | 20.25M | 28.31M | 16.41M | 16.42M | 14.75M | 19.37M | 32.71M | 28.08M | 28.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 42.68M | 34.24M | 27.05M | 21.26M | 25.38M | 28.45M | 32.92M | 31.07M | 16.81M | 0.00 | 28.87M | 20.84M | 0.00 | 53.20M | 44.97M | 45.26M | 57.85M |
| Selling & Marketing | 179.01M | 54.06M | 148.17M | 102.69M | 111.05M | 157.38M | 153.16M | 173.62M | 61.82M | 0.00 | 120.23M | 91.89M | 0.00 | 175.58M | 185.43M | 195.17M | 156.57M |
| SG&A | 555.63M | 88.29M | 175.22M | 123.95M | 136.44M | 185.83M | 186.08M | 204.69M | 78.63M | 336.13M | 512.41M | 422.03M | 0.00 | 228.78M | 230.40M | 240.43M | 214.41M |
| Other Expenses | 0.00 | 9.41M | 17.34M | 7.73M | 9.30M | 965.00K | 1.57M | 830.85M | 744.54M | 775.70M | 705.03M | 193.38K | 27.36K | 225.70M | 205.78M | 175.30M | 141.95M |
| Operating Expenses | 555.63M | 1.15B | 967.88M | 822.16M | 881.02M | 929.88M | 965.21M | 1.04B | 823.17M | 775.70M | 705.03M | 565.53M | 522.09M | 454.48M | 436.18M | 415.74M | 356.37M |
| Cost & Expenses | 3.16B | 2.88B | 2.67B | 2.33B | 1.74B | 2.13B | 1.99B | 2.21B | 1.90B | 1.77B | 1.66B | 1.35B | 1.29B | 1.07B | 1.04B | 947.80M | 785.06M |
| Interest Income | 3.76M | 2.31M | 3.70M | 3.14M | 3.88M | 5.53M | 2.19M | 2.50M | 3.04M | 2.92M | 1.62M | 1.79M | 1.97M | 743.27K | 752.14K | 1.14M | 1.10M |
| Interest Expense | 152.58M | 121.87M | 85.08M | 105.39M | 107.74M | 110.67M | 84.14M | 68.87M | 47.06M | 51.01M | 70.77M | 79.66M | 61.37M | 58.05M | 62.60M | 47.12M | 27.28M |
| Depreciation & Amortization | 100.71M | 91.28M | 90.40M | 95.21M | 76.78M | 61.55M | 67.71M | 64.91M | 70.09M | 70.23M | 47.40M | 48.12M | 41.31M | 29.01M | 28.07M | 19.57M | 18.63M |
| EBITDA | 320.23M | 245.00M | 287.64M | 257.82M | 48.88M | 186.92M | 189.26M | 178.53M | 161.32M | 181.97M | 184.43M | 172.19M | 148.46M | 107.85M | 60.10M | 111.49M | 93.09M |
| EBITDA Ratio | 9.44% | 8.57% | 8.71% | 9.67% | 2.86% | 7.46% | 8.63% | 6.88% | 7.33% | 9.00% | 9.99% | 11.65% | 9.97% | 9.44% | 3.86% | 10.82% | 10.66% |
| Operating Income | 214.57M | 169.35M | 144.36M | 170.88M | -26.13M | 117.05M | 105.95M | 77.40M | 80.28M | 103.84M | 131.37M | 124.17M | 106.76M | 73.16M | 26.07M | 86.98M | 72.29M |
| Operating Income Ratio | 6.33% | 5.57% | 5.13% | 6.82% | -1.53% | 5.20% | 5.06% | 3.38% | 4.05% | 5.55% | 7.34% | 8.39% | 7.64% | 6.40% | 2.45% | 8.41% | 8.43% |
| Total Other Income/Expenses | -124.10M | -129.75M | -488.46M | -99.62M | -79.53M | -117.30M | -76.85M | -54.48M | -51.94M | -60.83M | -65.11M | -73.17M | -63.49M | -62.78M | -35.13M | -45.97M | -30.26M |
| Income Before Tax | 90.47M | 47.49M | 91.83M | 41.03M | -135.29M | -2.03M | 28.83M | 23.61M | 26.49M | 47.40M | 66.26M | 50.89M | 44.55M | 10.38M | -9.04M | 40.56M | 42.03M |
| Income Before Tax Ratio | 2.67% | 1.56% | 3.27% | 1.64% | -7.91% | -0.09% | 1.38% | 1.03% | 1.34% | 2.53% | 3.70% | 3.44% | 3.19% | 0.91% | -0.85% | 3.92% | 4.90% |
| Income Tax Expense | 16.02M | 21.29M | 34.78M | -6.10M | -6.38M | -23.55M | 25.07M | 30.98M | 23.90M | 11.87M | 15.54M | 8.06M | 6.98M | 6.30M | 5.23M | 10.63M | 13.46M |
| Net Income | 73.92M | 25.72M | 56.12M | 47.42M | -122.18M | 37.88M | 27.82M | 19.86M | 14.05M | 36.28M | 50.72M | 42.84M | 37.57M | 4.08M | -14.29M | 29.93M | 28.57M |
| Net Income Ratio | 2.18% | 0.85% | 2.00% | 1.89% | -7.14% | 1.68% | 1.33% | 0.87% | 0.71% | 1.94% | 2.84% | 2.90% | 2.69% | 0.36% | -1.35% | 2.89% | 3.33% |
| EPS | 4.94 | 1.64 | 3.79 | 3.34 | -8.62 | 2.67 | 1.96 | 1.24 | 1.09 | 2.83 | 4.77 | 4.05 | 3.57 | 0.45 | -1.36 | 2.85 | 2.74 |
| EPS Diluted | 4.68 | 1.64 | 3.71 | 3.34 | -8.62 | 2.67 | 1.96 | 1.24 | 1.09 | 2.80 | 4.60 | 4.05 | 3.57 | 0.45 | -1.36 | 2.85 | 2.65 |
| Weighted Avg Shares Out | 14.96M | 15.69M | 14.82M | 14.20M | 14.17M | 14.17M | 14.17M | 14.17M | 12.87M | 12.80M | 10.64M | 10.57M | 10.53M | 10.48M | 10.48M | 10.46M | 10.45M |
| Weighted Avg Shares Out (Dil) | 15.81M | 15.69M | 15.14M | 14.20M | 14.17M | 14.17M | 14.17M | 14.17M | 12.87M | 12.95M | 11.02M | 10.57M | 10.53M | 10.53M | 10.53M | 10.55M | 10.74M |
Source: https://incomestatements.info
Category: Stock Reports